Semaglutide studies: 1,194 papers with results
Page 20 of 24
- Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.
Gofron KK · Nutrients · 2025
Other design · 3 results
- The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.
Corcoran E · Molecular and cellular neurosciences · 2026
Other design · 7 results
- Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach.
Palasantzas VEJM · Nutrients · 2026
In vitro (cells) · 1 result
- Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
Old V · Journal of cachexia, sarcopenia and muscle · 2026
In vitro (cells) · mouse · 22 results
- A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.
Rahman E · Aesthetic plastic surgery · 2026
In silico · 6 results
- Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.
McEwan P · Journal of medical economics · 2025
In silico · 12 results
- Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S · Frontiers in public health · 2023
In silico · 3 results
- Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
Overgaard RV · Diabetes, obesity & metabolism · 2019
In silico · 6 results
- Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States.
Liu L · Journal of managed care & specialty pharmacy · 2025
In silico · 12 results
- 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
Niu S · Diabetes, obesity & metabolism · 2024
In silico · 9 results
- Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.
Wu CC · Obesity (Silver Spring, Md.) · 2025
In silico · 4 results
- Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
Kan M · Diabetes, obesity & metabolism · 2023
In silico · 9 results
- Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
Hu S · Diabetes, obesity & metabolism · 2024
In silico · 6 results
- Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.
Rossing P · Cardiovascular diabetology · 2025
In silico · 7 results
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Johansson E · Journal of medical economics · 2026
In silico · 6 results
- Cost-effectiveness of endoscopic treatments for obesity: a clinical evidence map and systematic review to inform a model-based cost-effectiveness analysis.
Albon E · Health technology assessment (Winchester, England) · 2025
In silico · 1 result
- Impact of GLP-1 receptor agonists on stroke, subarachnoid hemorrhage, and intracerebral hemorrhage: a propensity-matched multi-institutional cohort study.
Costa M · Journal of neurosurgery · 2026
Not a test of Semaglutide alone · 80 results
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.
Galli M · Journal of the American College of Cardiology · 2025
Not a test of Semaglutide alone · 45 results
- Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.
Ko A · Annals of internal medicine · 2026
Not a test of Semaglutide alone · 26 results
- GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
Sawicka-Gutaj N · International journal of obesity (2005) · 2026
Not a test of Semaglutide alone · 26 results
- Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Martín V · Advances in therapy · 2020
Not a test of Semaglutide alone · 17 results
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.
McCall KL · Expert opinion on drug safety · 2026
Not a test of Semaglutide alone · 36 results
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.
Shah J · American journal of ophthalmology · 2026
Not a test of Semaglutide alone · 48 results
- Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm.
Marzolla V · Reports (MDPI) · 2026
Not a test of Semaglutide alone · 12 results
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA · The lancet. Diabetes & endocrinology · 2018
Not a test of Semaglutide alone · 22 results
- Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Harrison SA · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
Not a test of Semaglutide alone · 22 results
- Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis.
Jia A · Frontiers in cardiovascular medicine · 2025
Not a test of Semaglutide alone · 33 results
- Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.
Nanah MH · Crohn's & colitis 360 · 2026
Not a test of Semaglutide alone · 44 results
- The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Malkin SJP · Diabetology & metabolic syndrome · 2022
Not a test of Semaglutide alone · 10 results
- Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Lee MMY · Diabetes care · 2025
Not a test of Semaglutide alone · 9 results
- Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.
Nieto LM · The American journal of gastroenterology · 2026
Not a test of Semaglutide alone · 36 results
- A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.
Daniel S · Journal of drugs in dermatology : JDD · 2025
Not a test of Semaglutide alone · 27 results
- Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
Feng Z · Frontiers in pharmacology · 2023
Not a test of Semaglutide alone · 11 results
- Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.
Abdallah H · Obesity surgery · 2025
Not a test of Semaglutide alone · 18 results
- Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study.
Koide Y · Frontiers in clinical diabetes and healthcare · 2025
Not a test of Semaglutide alone · 27 results
- Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
Cui J · Journal of managed care & specialty pharmacy · 2021
Not a test of Semaglutide alone · 10 results
- Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.
Le Y · Foot & ankle specialist · 2026
Not a test of Semaglutide alone · 27 results
- Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.
St-Pierre J · Digestive diseases and sciences · 2024
Not a test of Semaglutide alone · 16 results
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
Ahmed M · Diabetes, obesity & metabolism · 2026
Not a test of Semaglutide alone · 18 results
- GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.
Gonzalez F · Journal of pediatric endocrinology & metabolism : JPEM · 2026
Not a test of Semaglutide alone · 24 results
- Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.
White RT · Pharmacotherapy · 2026
Not a test of Semaglutide alone · 16 results
- Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.
Bruno A · Aesthetic plastic surgery · 2026
Not a test of Semaglutide alone · 16 results
- Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
Long W · Pakistan journal of pharmaceutical sciences · 2026
Not a test of Semaglutide alone · 8 results
- Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.
Al Ozairi E · Diabetes/metabolism research and reviews · 2026
Not a test of Semaglutide alone · 24 results
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Davies MJ · The New England journal of medicine · 2025
Not a test of Semaglutide alone · 14 results
- The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.
Austregésilo de Athayde De Hollanda Morais B · Journal of diabetes and its complications · 2024
Not a test of Semaglutide alone · 14 results
- Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.
Al Refaie A · Endocrine · 2025
Not a test of Semaglutide alone · 14 results
- Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review.
Deameh MG · The journal of sexual medicine · 2026
Not a test of Semaglutide alone · 14 results
- Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.
Chen B · Clinical nutrition ESPEN · 2025
Not a test of Semaglutide alone · 7 results
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Rosenstock J · Lancet (London, England) · 2026
Not a test of Semaglutide alone · 14 results